Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
Protester camping outside Cambridgeshire 'puppy killing monster factory' faces removal from area
John Curtin, 62, has been living in a tent outside the MBR Acres research site in protest of their medical experimentation ...